RxDoctor Payments Data

Ronald Garbutt, MD

Psychiatry · Pittsburgh, PANPI 1790776979

Payments from drug & device makers

$817in general payments, 2019–2025

Across 45 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$254
  • Otsuka America Pharmaceutical, Inc.$135
  • Vanda Pharmaceuticals Inc.$125
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$81
  • Sunovion Pharmaceuticals Inc.$60
  • Indivior Inc.$42
  • plus $121 from 7 others

What the payments were for

  • Food & beverage$817100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$817 in reported general payments places this provider in the 75th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,743
Medicare patients
13
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate75$259,307
Austedo XrDeutetrabenazine13$178,008
Abilify MaintenaAripiprazole27$79,165
Risperdal ConstaRisperidone Microspheres51$64,822
VraylarCariprazine Hcl44$54,541
CaplytaLumateperone Tosylate25$38,581
RexultiBrexpiprazole16$22,095
LybalviOlanzapine/Samidorphan Malate13$21,175
Clozapine202$13,367
Lurasidone Hcl44$11,278
Paliperidone ErPaliperidone52$11,194
Aripiprazole154$9,562
VyvanseLisdexamfetamine Dimesylate21$8,025
Gabapentin201$3,924
Quetiapine Fumarate151$3,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$17$324,129126 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$11$178,00813 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$135$101,26043 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$81$38,58125 claims
Alkermes, Inc.Lybalvi$254$21,17513 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$21$8,02521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →